glp-1-based therapy Expanding applications of therapies based on GLP1 GLP-1 receptor agonists and next-generation

When consumed in standard capsule or tablet form, glutathione is rapidly broken down by digestive enzymes and stomach acid before it can reach systemic circulation

(4) Tocopheryl Acetate (Germany, 96% purity)

Disposing of unused, expired, or deteriorated reconstituted retatrutide requires careful consideration to protect public health and comply with applicable regulations

Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice

Kodama K, Tojjar D, Yamada S, et al

GLP-1 also regulates the growth of the Islets of Langerhans and enhances beta cell proliferation and it supports the health of the cells so they have an improved, longer and healthier life span